CA-NETAPP
10.5.2022 14:02:04 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced that NetApp EF600 all-flash NVMe storage combined with the BeeGFS parallel file system is now certified for NVIDIA DGX SuperPOD ™. The new certification simplifies artificial intelligence (AI) and high-performance computing (HPC) infrastructure to enable faster implementation of these use cases.
Since 2018, NetApp and NVIDIA have served hundreds of customers with a range of solutions, from building AI Centers of Excellence to solving massive-scale AI training challenges. The qualification of NetApp EF600 and BeeGFS file system for DGX SuperPOD is the latest addition to a complete set of AI solutions that have been developed by the companies.
“The NetApp and NVIDIA alliance has delivered industry-leading innovation for years, and this new qualification for NVIDIA DGX SuperPOD builds on that momentum,” said Phil Brotherton, Vice President of Solutions and Alliances at NetApp. “As performance and data demands are exploding, NVIDIA DGX SuperPOD, coupled with ONTAP AI platform and DGX Foundry AI service, ensures our customers get the best-in-class model training infrastructure, with the full support of AI industry leaders.”
“Organizations modernizing their business with AI and HPC need performance, flexibility and choice as they architect their infrastructure,” said Charlie Boyle, Vice President of DGX systems at NVIDIA. “Our collaboration with NetApp enables customers building their own AI Centers of Excellence to now choose NetApp storage for their NVIDIA DGX SuperPOD, as well as use the same leading platform available as hosted infrastructure through NVIDIA DGX Foundry.”
“We’re thrilled to be working with NetApp and NVIDIA to build an HPC/AI Center of Excellence with NVIDIA DGX systems so applied learning students can experience supercomputing and high-performance computing infrastructure,” said Tonya Witherspoon, Associate Vice President, Industry Engagement & Applied Learning at Wichita State University. “NetApp is a digital fabric anchor of the innovation campus, and we can’t wait to develop the next generation of talent in this exciting space.”
Broad Portfolio of AI Infrastructure Solutions
NetApp’s portfolio of NVIDIA-accelerated solutions includes ONTAP AI to eliminate guesswork for faster adoption by using a field-proven reference architecture as well as a preconfigured, integrated solution that is easy to procure and deploy in a turnkey manner.
Also included is NVIDIA DGX Foundry , which features NVIDIA Base Command software and NetApp Keystone Flex Subscription. This combination provides a world-class hosted infrastructure solution for businesses and their data scientists who need a premium AI development experience without the struggle of building it themselves.
With today’s announcement, organizations can also build their AI Centers of Excellence leveraging the power of DGX SuperPOD on premises in combination with NetApp storage.
NetApp, in collaboration with NVIDIA, also offers tailored solutions for a variety of industries, including financial services , medicine , manufacturing , retail , higher education and government, and has sponsored and facilitated ideation workshops for customers embarking on AI journeys to accelerate success while mitigating risk.
“The AI lifecycle focus has moved up the development stack and away from the infrastructure management, driving the need for converged solutions and services that make it easier for organizations to simplify their infrastructure investments for AI use cases deployments,” said Ritu Jyoti, Group Vice President, AI/Automation Research & Advisory at IDC. “DGX SuperPOD is the latest milestone in a prolific partnership between NetApp and NVIDIA to address this need, and NetApp is well positioned to help customers solve their data management challenges regardless of where it resides.”
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom